Denied health claims on lactose digestion, DNA integrity and improved arterial stiffness
European Union
May 13, 2022
Commission Regulation (EU) 2022/719 of 10 May 2022 refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health.
Rejected health claims
Application – Relevant provisions of Regulation (EC) No 1924/2006 |
Nutrient, substance, food or food category |
Claim |
EFSA opinion reference |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data |
Bifidobacterium animalis subsp. lactis Bi-07 (Bi-07) |
Bifidobacterium animalis subsp. lactis Bi-07 contributes to the improvement of lactose digestion in individuals who have difficulty digesting lactose |
Q-2020-00024 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data |
Coffee C21, a blend of pure Arabica roast coffees (Coffea arabica L.) without any non-coffee ingredients |
Regular consumption of Coffee C21 contributes to the maintenance of DNA integrity in cells of the body |
Q-2019-00423 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data |
MenaQ7®, vitamin K2 as menaquinone-7 |
MenaQ7®, vitamin K2 as menaquinone-7, improves arterial stiffness |
Q-2019-00229 |
For further information (in English), click on the Link